Results 121 to 130 of about 50,964 (281)

Castration-resistant prostate cancer: potential targets and therapies

, 2012
Aijaz Parray,1 Hifzur R Siddique,1 Sanjeev Nanda,1,2 Badrinath R Konety,3 Mohammad Saleem1,3,41Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, 2Department of Internal Medicine, Mayo Clinic Health Systems,
Konety BR, Nanda S, Saleem M, Siddique HR, Parray A   +4 more
core  

Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities

Research and Reports in Urology, 2023
Eun-mi Yu,1 Min Woo Hwang,2 Jeanny B Aragon-Ching1 1GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA; 2Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA, USACorrespondence: Jeanny B Aragon-Ching, Clinical Program ...
Yu EM, Hwang MW, Aragon-Ching JB
doaj  

O‐GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A‐TRIM22 Interaction

Cancer Science, EarlyView.
Lysine acetyltransferase 2A (KAT2A) is a transcriptional coactivator and a member of the Histone Acetyltransferase (HAT) family. While altered KAT2A activity has been implicated in various cancers, its role in bladder cancer (BLCA) remains poorly understood.
Wenjie Yang, Zhaoheng Jin, Ziyi Li, Weifeng Xu, Yingjie Li, Yueqiang Peng, Jie Dong, Lin Ma, Zhigang Ji   +8 more
wiley   +1 more source

Gene amplifications associated with the development of hormone- resistant prostate cancer [PDF]

, 2003
Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential.
Krishnan, S., Witton, C.J., Edwards, J., Bartlett, J.M.S.   +3 more
core  

Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer

Prostate Cancer, 2011
Almost all patients who succumb to prostate cancer die of metastatic castration-resistant disease. Although docetaxel is the standard treatment for this disease and is associated with modest prolongation of survival, there is an urgent need for novel ...
Takahiro Inoue, Osamu Ogawa
doaj   +1 more source

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate

Histopathology, EarlyView.
FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao, Jun Yao, Hossein Hosseini, Ezra Baraban, Ruihe Lin, Charles C. Guo, Lei Huo, Wei Lu, Khaja Khan, Shufang Wang, Luisa Maren Solis Soto, Qingqing Ding   +11 more
wiley   +1 more source

Contrast Agents for Enhanced Bioimaging: A Comprehensive Review

ChemBioChem, Volume 27, Issue 13, 14 July 2026.
Contrast agents, especially those that are nanoparticle‐based, are revolutionizing bioimaging by enabling highly sensitive, specific, and early‐stage diagnosis of diseases like cancer, using clinical imaging modalities such as CT, MRI, PET, and SPECT.
Paulo Sérgio Taube, Donald Fernandes, Arthur Abinader Vasconcelos, Hugo de Campos Braga, Alan Kelbis Oliveira Lima, José Arnaldo Santana Costa, Karla Furtado Andriani, Ester da Cunha Meira Santos, Antonio Jorge Silva Araújo Junior, Hauster Maximiler Campos de Paula, Wallace Júnio Reis, Kashif Gul, Nida Wahab, Luis Carlos Resio, Elisa Kawana Leal dos Santos, Márcio Peres de Araujo, Matheus Allen P. da Silva, Juliana Paula da Silva   +17 more
wiley   +1 more source

Abiraterone in the treatment of metastatic castration-resistant prostate cancer

, 2014
Elahe A Mostaghel Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Abstract: Androgen deprivation therapy remains the single most effective treatment for the initial therapy of advanced prostate cancer, but is ...
Mostaghel EA
core  

PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration

iScience
Summary: Tumor plasticity drives the emergence of castration-resistant and neuroendocrine prostate cancer following androgen-deprivation therapy (ADT).
Rocco Cipolla, Marc Gabriel, Ugo Szachnowski, Zhimin Wang, Martina Romani, Giorgia Ianese Regin, Micaela Piemontese, Virginie Firlej, Marina Pinskaya, Antonin Morillon   +9 more
doaj   +1 more source

Eyes Toward the Clinic: Selective Inhibition and Degradation Approaches to Bromodomain‐Containing Proteins

ChemBioChem, Volume 27, Issue 13, 14 July 2026.
The function of bromodomain‐containing proteins in regulating gene transcription is reviewed here, including the development of chemical probes and targeted protein degradation modalities (e.g., PROTACs). This extends to clinical efforts targeting the BET bromodomain‐containing proteins. Challenges of selectivity, future prospects, and the differential
Cole R. Scholtz, William C. K. Pomerantz
wiley   +1 more source